Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.49%165.630.7%$1350.47m
LLYEli Lilly & Co. 1.50%326.361.1%$1083.66m
ABBVAbbVie, Inc. 2.23%141.411.9%$871.30m
PFEPfizer Inc. 1.16%44.650.9%$807.38m
BMYBristol-Myers Squibb Co. 1.59%71.651.0%$784.94m
MRKMerck & Co., Inc. 1.12%88.530.7%$718.32m
AZNAstraZeneca Plc 2.43%56.901.0%$396.91m
ALNYAlnylam Pharmaceuticals, Inc. -0.74%195.348.2%$215.79m
GSKGSK Plc 2.50%31.010.3%$214.92m
NVSNovartis AG 2.22%78.370.2%$206.13m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.485.4%$191.16m
IDXXIDEXX Laboratories, Inc. 3.40%348.133.9%$190.55m
HZNPHorizon Therapeutics Plc 1.56%65.265.4%$176.35m
ATXIAvenue Therapeutics, Inc. 21.81%14.020.0%$169.69m
SRPTSarepta Therapeutics, Inc. 0.32%110.3012.4%$137.18m

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.